title: [Study of cross-activity of Streptococcus pneumoniae antigen preparations].
abstract: OBJECTIVE
  Study cross-activity of S. pneumoniae antigen preparations.
  
  
  METHODS
  Antigen preparations were obtained by ultrasound disintegration (from bacteria in R-form), extraction with water (from serotype 3 bacteria), cetavlon and trichloroacetic acid (from serotype 6A bacteria). Chemical composition and immunochemic properties of preparations were studied by contemporary methods as well as in experiments with direct and cross-protection of mice from infection.
  
  
  RESULTS
  3 of 4 preparations (except ultrasound disintegrate) had approximately 30% of protein. In immunodiffusion reaction they interacted with hyper immune rabbit sera obtained against 12 various pneumococcus serotypes--1, 3, 4, 6A, 6B, 9V, 9N, 14, 18C, 19A, 19F and 23F. In animal experiments 30 - 70% of mice were protected from subsequent infection with knowingly high dose of homologous and 3 heterologous pneumococcus strains. In immunoblotting the highest number of components serologically active with heterologous sera was formed by cetavlon extract (12 - 23). Addition of capsule polysaccharides to the preparation increased its cross-protective activity.
  
  
  CONCLUSIONS
  By data set and the highest yield, water extract is reasonable for isolation of cross-reactive proteins of pneumococcus. Development of another method of extraction from cultural fluid is necessary for obtaining extracellular protein antigens. Generation of vaccines containing cross-reactive proteins of pneumococcus and capsule polysaccharides is a promising direction.
authors.forename: N P
authors.initials: NP
authors.lastname: Vaneeva
authors.forename: D S
authors.initials: DS
authors.lastname: Vorob'ev
authors.forename: N V
authors.initials: NV
authors.lastname: Grishchenko
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: N E
authors.initials: NE
authors.lastname: Iastrebova
authors.forename: N G
authors.initials: NG
authors.lastname: Kalina
authors.forename: S I
authors.initials: SI
authors.lastname: Elkina
authors.forename: A V
authors.initials: AV
authors.lastname: Zubkov
authors.forename: P G
authors.initials: PG
authors.lastname: Aparin
authors.forename: V L
authors.initials: VL
authors.lastname: L'vov
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhaĭlova
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000276:immunology; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D016667:Bacterial Capsules / Q000737:chemistry / Q000276:immunology; D056738:Cross Protection; D006801:Humans; D007114:Immunization; D005779:Immunodiffusion; D051379:Mice; D008807:Mice, Inbred BALB C; D011008:Pneumococcal Infections / Q000276:immunology / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology / Q000302:isolation & purification; D011817:Rabbits; D013296:Streptococcus pneumoniae / Q000276:immunology*; D015996:Survival Rate
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial